Albany Molecular Research (AMRI) has licensed tech from Florida biopharma Teewinot to produce and sell the first commercially available cannabichromene acid analytical standard. The cannabichromene ...
ALBANY, N.Y., Jan. 9, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has acquired the outstanding equity interests of Aptuit's Glasgow, UK business and has entered into a definitive ...
BUFFALO, N.Y. -- As further evidence of Governor Andrew M. Cuomo's successful establishment of a dynamic and growing bio-pharma sector in Buffalo, New York, Albany Molecular Research Inc. (NASDAQ: ...
Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced that the company has been chosen to support ...
The company will join the network of approved manufacturers of the lipid excipients. Albany Molecular Research (AMRI) announced on Feb. 25, 2021 that it has been selected to provide support for the ...
ALBANY, N.Y.--(BUSINESS WIRE)--Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced expanded access ...
AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes Biosolutions. The system will be deployed at AMRI's Integrated Drug Discovery Center and, in accordance with the ...
AMRI’s recent financial performance has raised questions about whether the state is putting its money behind the right company. AMRI had a combined $112 million in losses between 2009 and 2011, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results